Pharmaceutical composition for preventing, treating or development-inhibiting simple retinopathy and preproliferative retinopathy

Abstract

To provide a pharmaceutical composition for preventing, treating or development-inhibiting simple retinopathy or preproliferative retinopathy, comprising a compound having angiotensin II antagonistic activity, or a salt thereof.

1 - 14 . (canceled)  
   
   
       15 . A method for preventing, treating or inhibiting development of simple retinopathy or preproliferative retinopathy in a mammal in need thereof, which comprises administering an effective amount of a compound having angiotensin II antagonistic activity, or a prodrug thereof, or a pharmaceutically acceptable salt thereof, to the mammal.  
   
   
       16 . A method for improving retinal potency or retinal edema in a mammal in need thereof, which comprises administering an effective amount of a compound having angiotensin II antagonistic activity, or a prodrug thereof, or a pharmaceutically acceptable salt thereof, to the mammal.  
   
   
       17 . The method according to  claim 15  or  16 , wherein the compound having angiotensin II antagonistic activity is a non-peptide compound.  
   
   
       18 . The method according to  claim 15  or  16 , wherein the compound having angiotensin II antagonistic activity is a compound having an oxygen atom in its molecule.  
   
   
       19 . The method according to  claim 15  or  16 , wherein the compound having angiotensin II antagonistic activity is a compound having an ether linkage or a carbonyl group.  
   
   
       20 . The method according to  claim 15  or  16 , wherein the compound having angiotensin II antagonistic activity is a compound of the formula:  
     
       
         
         
             
             
         
       
     
     wherein R 1  is a group capable of forming an anion or a group capable of converting thereinto, X is a bond or a spacer having an atomic chain length of 2 or less, n is an integer of 1 or 2, ring A is a benzene ring having an optional substituent in addition to R 2 , R 2  is a group capable of forming an anion or a group capable of converting thereinto, and R 3  is an optionally substituted hydrocarbon residue which may bind through a hetero-atom.  
   
   
       21 . The method according to  claim 15  or  16 , wherein the compound having angiotensin II antagonistic activity is Losartan, Eprosartan, Candesartan, Candesartan cilexetil, Valsartan, Telmisartan, Irbesartan or Tasosartan.  
   
   
       22 . The method according to  claim 15  or  16 , wherein the compound having angiotensin II antagonistic activity is 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylic acid.  
   
   
       23 . The method according to  claim 15  or  16 , wherein the compound having angiotensin II antagonistic activity is 1-(cyclohexyloxycarbonyloxy)ethyl-2-ethoxy-1-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate.  
   
   
       24 . The method according to  claim 15  or  16 , wherein the compound having angiotensin II antagonistic activity is 2-ethoxy-1-[[2′-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylic acid.